Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 24Neoplasm Metastasis 11Stomach Neoplasms 6Pancreatic Neoplasms 4Ovarian Neoplasms 4Endometrial Neoplasms 4Colorectal Neoplasms 4Salivary Gland Neoplasms 3Esophageal Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Adenocarcinoma 3Triple Negative Breast Neoplasms 2Recurrence 2Prostatic Neoplasms 2Neoplasms 2Adenocarcinoma Of Esophagus 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Unresectable Locally Recurrent Breast Cancer 1Thyroid Neoplasms 1Testicular Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Osteosarcoma 1

Interventions

trastuzumab deruxtecan 1sacituzumab govitecan 1Temozolomide 1Social Determinants of Health 1Methylprednisolone 1Irinotecan 1Cefixime 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Drug-Related Side Effects and Adverse Reactions × trastuzumab deruxtecan × 90 days × Clear all
NCT07582887 2026-05-13

Impact of Genetic Variants on the Toxicity of Antibody-Drug Conjugates in Locally Advanced or Metastatic Breast Cancer: The Role of the UGT1A1 Gene as a Predictive Biomarker of Therapeutic Response

Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental

Recruiting
70 enrolled
Breast

Breast Neoplasms, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon ⚡